Quoin Pharma Files 8-K on Officer/Director Changes

TL;DR

Quoin Pharma's 8-K shows leadership changes and new comp plans.

AI Summary

Quoin Pharmaceuticals, Ltd. filed an 8-K on November 17, 2025, reporting events as of November 14, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates potential shifts in Quoin Pharmaceuticals' leadership and executive compensation structure, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with updates to compensatory arrangements, can signal internal shifts that may affect company strategy and performance.

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K
• Cellect Biotechnology Ltd. (company) — Former company name
• Cellect Biomed Ltd. (company) — Former company name

FAQ

Filing Documents

• tm2531454d1_8k.htm (8-K) — 34KB
• tm2531454d1_ex10-1.htm (EX-10.1) — 25KB
• tm2531454d1_ex10-2.htm (EX-10.2) — 25KB
• 0001104659-25-113237.txt ( ) — 259KB
• qnrx-20251114.xsd (EX-101.SCH) — 3KB
• qnrx-20251114_lab.xml (EX-101.LAB) — 33KB
• qnrx-20251114_pre.xml (EX-101.PRE) — 22KB
• tm2531454d1_8k_htm.xml (XML) — 4KB

02. Departure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 14, 2025, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Quoin Pharmaceuticals Ltd. (the "Company") approved forms of award agreements (the "Award Agreements") to be used for the grant of stock options to directors and executive officers under the Company's 2025 Equity Incentive Plan (the "Plan"). The Award Agreements were adopted in order to facilitate the Company's grant of equity awards with a variety of terms and vesting criteria as permitted by the Plan. The forms of Award Agreements, together with the Plan, provide the following: The exercise price of an option may be paid in cash, by either certified or bank check, by wire transfer of immediately available funds, by delivery of an irrevocable direction to a securities broker approved by the Company to sell shares and to deliver all or part of the sales proceeds to the Company, by delivery of an irrevocable direction to a securities broker or lender approved by the Company to pledge shares as security for a loan and to deliver all or part of the loan proceeds to the Company, by applying the Cashless Exercise Mechanism (as defined in the Plan), or in such other manner as the Committee shall determine. If a participant's employment or service to the Company is terminated, outstanding vested and unvested awards will be subject to the following treatment: Reason for Termination Effect on Awards Death or Disability All awards that are unvested at the time of a grantee's termination shall terminate on the date of such termination, and all awards of such grantee that are vested and exercisable may be exercised by the grantee or the grantee's estate at any time within one (1) year after the death of the grantee (which results in the grantee's termination or occurs within the three month period aft

01. Financial

Item 9.01. Financial (d) Exhibits. The following exhibits are filed or furnished, as applicable, with this Report: Exhibit Number Description 10.1 Form of Incentive Stock Option Grant Notification Letter 10.2 Form of Non-Qualified Stock Option Grant Notification Letter 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: November 17, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR